A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity
Authors:
- R. D. PettyRPR. D. Petty
- M. C. NicolsonMNM. C. Nicolson
- S. SkariaSSS. Skaria
- T. S. SinclairTST. S. Sinclair
- L. M. SamuelLSL. M. Samuel
- M. KoruthMKM. Koruth
- 1 July 2003
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 14 (7) , 1100-1105
Abstract
Background: The effective treatment of unresectable pancreatic carcinoma represents a formidable challenge. There is a need to develop systemic therapies which combine efficacy with acceptable toxicity. The current ‘gold standard’ gemcitabine gives an objective response rate of the order of 20% and median survival up to 6 months. Here we have evaluated the efficacy and toxicity of mitomycin C, cisplatin and protracted infusional 5-fluorouracil (MCF). Patients and methods: Forty-five patients with locally advanced (13 patients) or metastatic (32 patients) pancreatic carcinoma were treated with mitomycin C 7 mg/m2 6 weekly, cisplatin 60 mg/m2 3 weekly and protracted venous infusion 5-FU 300 mg/m2/day. Patients were evaluated for response after three cycles and received six cycles in total in the absence of progressive disease or poor tolerance. Median age was 62 (45–75) years; 41 patients were World Health Organization performance status 0–1. Results: Treatment was well tolerated with 36 (84%) patients completing three or more cycles. Grade 3 or 4 toxicities were uncommon: anaemia in three patients (7%), mucositis in two (5%), nausea and vomiting in three (7%) and diarrhoea in one (1%). An objective response was seen in 21 (46%) patients. There was one complete response. The median survival overall was 7.1 months and 10.5 months in responders. The median duration of response was 4.3 months. One-year survival was 29%, 2-year survival was 18%. Conclusions: MCF combines efficacy with low toxicity in the treatment of advanced pancreatic carcinoma. The efficacy is at least comparable and may be superior to single-agent gemcitabine and MCF may therefore provide a cost-effective alternative.Keywords
This publication has 23 references indexed in Scilit:
- Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II StudyJournal of Clinical Oncology, 2002
- A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinomaCancer, 2001
- Definitive Results of a Phase II Trial of Cisplatin, Epirubicin, Continuous-Infusion Fluorouracil, and Gemcitabine in Stage IV Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2001
- Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)Annals of Oncology, 2001
- A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancerAnnals of Oncology, 2000
- A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296)Oncology, 2000
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996
- Phase II study of gemcitabine in patients with advanced pancreatic cancerBritish Journal of Cancer, 1996
- Cisplatin and protracted venous infusion 5-fluorouracil (CF) — good symptom relief with low toxicity in advanced pancreatic carcinomaAnnals of Oncology, 1995